智通财经记者 | 袁颖琪 智通财经编辑 | 陈菲遐 一份亮眼年报背后，高悬的商誉、恶化的现金流和激增的库存正编织一张危险网。 日前，开润股份（300577.SZ）三位高管的减持计划引起市场关注。投资者发现，这家公司2024年净利 润暴增229%、2025年一季度归母净利润增长20%，但股价年内跌幅达15.88%，与业绩形成尖锐背离。 2025年初，开润股份向资本市场交出一份亮眼成绩单： 2024年营业收入42.40亿元，同比大幅增长 36.6%；归属于上市公司股东净利润3.81亿元，同比飙升229.5%，创下历史新高。 今年一季度，开润股份营业收入增长35.57%达到12.35亿元，归母净利润增长20.12%达到8500万元。这 一业绩增速远超行业平均水平。然而，细究财务数据会发现，公司业绩暴增的幕后推手并非传统的内生 性增长，而是一次精心策划的并购交易——对上海嘉乐股份有限公司（下称上海嘉乐）的控股收购。 2024年6月，开润股份通过全资子公司滁州米润完成对上海嘉乐15.9%股权的收购，交易总价约2亿元。 收购完成后，开润股份对上海嘉乐的持股比例从35.94%上升至51.85%，实现了对这家服装代工企业的 ...

Core Viewpoint - The recent shareholding increase by Jiangxi Fangda Steel Group, a concerted action party of the controlling shareholder Fangda Group, in Northeast Pharmaceutical Group signifies a strong confidence in the company's intrinsic value and future prospects, marking a new chapter of high-quality development for the company [1][2][9] Group 1: Shareholding Increase - Fangda Steel has completed its shareholding increase plan, raising its stake in Northeast Pharmaceutical to nearly 56%, indicating a significant commitment beyond mere financial investment [1][2] - This action reflects a belief that the current market valuation does not accurately represent the company's true value and future potential, presenting an attractive opportunity for further investment [2][9] Group 2: Protection of Minority Investors - The controlling shareholder's investment serves as a protective measure for minority investors, reinforcing market expectations and demonstrating a commitment to long-term development [3][9] - The increase in shareholding does not alter the company's control structure, aiming to enhance investor confidence and promote sustainable growth [3] Group 3: Internal Growth Drivers - Northeast Pharmaceutical is focusing on "R&D innovation" and "international expansion" as dual engines for growth, transitioning from traditional to modern development models [4][5] - The recent achievement of obtaining the European Pharmacopoeia Certificate (CEP) for its active pharmaceutical ingredient signifies a major milestone, allowing the company to access high-value European markets [4] Group 4: Strategic Investments - The company has significantly increased its investment in R&D in the first quarter of 2025, reflecting a long-term vision amidst a cost-cutting trend in the pharmaceutical industry [5] - This strategic focus on R&D is expected to yield new products and establish competitive advantages, supporting the company's long-term value growth [5] Group 5: External Expansion - Northeast Pharmaceutical is also pursuing external growth through strategic acquisitions, such as the recent purchase of Beijing Dingcheng Peptide Source Biopharmaceutical Company, which enhances its product offerings and market reach [6][8] - The acquisition aims to create synergies in product lines and R&D capabilities, thereby increasing overall market penetration and brand influence [7][8] Group 6: Future Outlook - The combination of internal growth, strategic acquisitions, and strong support from the controlling shareholder positions Northeast Pharmaceutical for a significant value return and operational success [9] - The current developments suggest a pivotal moment for the company, indicating a successful transformation and potential for renewed market recognition [9]

大额交易引发市场关注 部分科创板公司筹划的重组标的规模庞大，市场影响深远。海光信息与中科曙光正筹划换股吸收合并方案，海光信息将通过发行A股股票方式吸收合并中科 曙光。中科曙光在高端计算、存储、云计算领域积累深厚，市值约906亿元。海光信息专注国产架构CPU、DCU等核心芯片设计，市值达3164亿元。 这一合并案例具有重要产业意义。从产业链角度分析，海光信息位于中科曙光业务上游环节。合并完成后将实现产业链深度整合，形成从芯片设计到系统应 用的完整布局。双方技术优势互补，有望提升整体竞争实力，对信息产业格局产生重要影响。 科创板重大资产重组市场持续升温，展现出强劲发展势头。Wind数据统计显示，"科创板八条"政策实施以来，科创板上市公司已披露重大资产重组方案达 105家。2025年开年至今，新增重大资产重组方案数量已达44家，市场参与度保持高位运行状态。 企业积极布局产业协同 多家科创板公司通过重大资产重组实现业务协同发展。奥浦迈近期发布公告，计划以发行股份及支付现金方式收购澎立生物100%股权。奥浦迈专注细胞培 养产品与服务，澎立生物则从事生物医药研发临床前CRO服务。交易完成后，双方将在客户资源、产品推广等方 ...